CRESCENT BIOPHARMA INC (CBIO)
Health Care · Clinical-stage oncology biotechnology · NASDAQ
A clinical-stage oncology biotech building a PD-1 x VEGF bispecific antibody and best-in-class antibody-drug conjugates to replace Keytruda as the foundational immuno-oncology backbone.
What CRESCENT BIOPHARMA INC does
Crescent Biopharma is a clinical-stage biotechnology company focused on developing transformative cancer therapies. The company is executing two core strategies: developing CR-001, a PD-1 x VEGF bispecific antibody designed to compete with pembrolizumab (Keytruda), and building a portfolio of best-in-class antibody-drug conjugates (ADCs) including CR-002 (PD-L1-directed ADC) and CR-003 (integrin beta-6-directed ADC). The company intends to combine these therapies to create synergistic combinations for multiple cancer types.
Themes: ["immuno-oncology / checkpoint inhibitors","antibody-drug conjugates (ADCs)","bispecific antibodies","oncology combination therapies","solid tumor treatment"]
Fundamentals
- Price$16.76 as of 2026-07-09 close
- Market cap$463M as of 2026-07-10
- 1-year return+13.3% as of 2026-07-09 close
- Net margin-990.3% as of 2026-07-10
- Gross margin-0.5% as of 2026-07-10
- ROE-102.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+413.7% as of 2026-07-10
- Beta1.23 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Merck (pembrolizumab / Keytruda)
- Bristol Myers Squibb (nivolumab / Opdivo)
- Akeso Biopharma / Summit Therapeutics (ivonescimab)
- Pfizer (ADC portfolio)
- Gilead Sciences (ADC portfolio)
- Seagen (ADC portfolio)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.